Our Pipeline: Solid, And Set For Further Growth
Identifying and developing products that will improve the health and quality of
life of patients remains a primary focus of Forest Laboratories. Our current product
pipeline includes therapies in all stages of development and across a wide range of
therapeutic areas, including asthma, cardiovascular disease, chronic obstructive
pulmonary disease, depression, diabetes, gastrointestinal disease, infectious
disease, and pain management. The following is a partial listing of our
pipeline products:
|
Aclidinium
|
COPD
|
NDA filed
|
|
Linaclotide
|
CC/IBS-C
|
NDA filed
|
|
Cariprazine
|
Schizophrenia/Bipolar Mania
|
Phase III – NDA projected ‘12
|
|
|
Levomilnacipran (F2695)
|
Major Depressive Disorder
|
Phase III – NDA projected ‘12
|
|
|
Aclidinium / Formoterol
|
COPD
|
Phase III
|
|
|
Apadenoson
|
Coronary Vasodilator
|
Phase III
|
|
|
Azimilide
|
Antiarrhythmic
|
Phase III
|
|
|
Proof of Concept
|
|
Cariprazine
|
MDD Adjunctive/Bipolar Depression
|
Phase II
|
|
|
Ceftazidime + Avibactam
|
Infectious Disease
|
Phase II
|
|
|
LAS 100977 (LABA)
|
Asthma/COPD
|
Phase II
|
|
|
GRT 6005/06
|
Pain Management
|
Phase II
|
|
|
Ceftaroline + Avibactam
|
Infectious Disease
|
Phase II
|
|
|
GK1-399
|
Diabetes
|
Phase I
|
|
Except for the historical information contained herein, this page contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties, including the
difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, the timely development
and launch of new products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any
subsequent SEC filings.
